M

Author

Marcus Chen

Markets & Equities Correspondent

Marcus Chen has covered global equity markets for 12 years, reporting on earnings season, stock listings, and corporate deal activity across US and Asian exchanges. He holds a CFA charter and previously worked as an equity research associate at a Singapore brokerage before moving into financial journalism. His reporting focuses on translating quarterly results and M&A activity into plain-language coverage for retail investors.

Covers:
  • stocks
  • markets
  • earnings
  • mergers-acquisitions
Latest by Marcus Chen
Immix Biopharma Stock Plummets After Report Reveals CMO Was a Fugitive

Stocks

Immix Biopharma Stock Plummets After Report Reveals CMO Was a Fugitive

Jul 20, 2026

Shares of Immix Biopharma plunged after an investigative report from STAT News revealed the company's recently hired Chief Medical Officer was a fugitive who had been evading law enforcement for nearly two decades. The disclosure has raised significant questions about the firm's executive vetting process ahead of a key clinical trial readout.